Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 19/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 7/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | MAP3K20 | Q9NYL2 | 7/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18115007 | 1.00 | THRB (0.51) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL29530607 | 0.91 | THRB (0.51) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL18115095 | 0.91 | THRB (0.51) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL18115116 | 0.90 | TGFBR1 (0.48) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL19998101 | 0.89 | TGFBR1 (0.50) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL18114922 | 0.89 | TGFBR1 (0.48) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL29530366 | 0.89 | TGFBR1 (0.48) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL29529529 | 0.88 | THRB (0.52) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL18115021 | 0.88 | THRB (0.52) | THRBTGFBR1TGFBR2MAPK14MAP3K20 | |
| SCHEMBL18114841 | 0.88 | TGFBR1 (0.47) | THRBTGFBR1TGFBR2MAPK14MAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11466018-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | THRB 102/4885TGFBR1 1/4885TGFBR2 2/4885 |
| US-11466018-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | THRB 102/4885TGFBR1 1/4885TGFBR2 2/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | THRB 86/4885TGFBR1 1/4885TGFBR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.